ArticleAntimicrobial agents and chemotherapy2000
Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine.
Article in Antimicrobial agents and chemotherapy, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 33 citations in OpenAlex.
- Leishmaniasis immunopathology-impact on design and use of vaccines, diagnostics and drugs.Seminars in immunopathology · 2020Review
- Oral treatment with T6-loaded yeast cell wall particles reduces the parasitemia in murine visceral leishmaniasis model.Scientific reports · 2019Article
- In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites.PLoS neglected tropical diseases · 2012Article
- Therapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2011Article
- The relationship between leishmaniasis and AIDS: the second 10 years.Clinical microbiology reviews · 2008Review
- Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.Antimicrobial agents and chemotherapy · 2007Article
- Miltefosine (Impavido): the first oral treatment against leishmaniasis.Medical microbiology and immunology · 2004Article
- Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.Antimicrobial agents and chemotherapy · 2002Article
- Clinical and experimental advances in treatment of visceral leishmaniasis.Antimicrobial agents and chemotherapy · 2001Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
T-cell-deficient nude mice infected with Leishmania donovani were treated with miltefosine and then given either no treatment or intermittent miltefosine. Intracellular visceral infection recurred in untreated mice but was suppressed by once- or twice-weekly oral administration of miltefosine. Miltefosine may be useful as oral maintenance therapy for T-cell-deficient patients with visceral leishmaniasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.